Several investigators1 have attempted the extraction of the essential Rh fraction which is undoubtedly present in human Rh-positive erythrocytes. More recently, Carter2 prepared an extract, called it Rh hapten and claimed the following characteristics for such material: (a) inability to generate specific anti-Rh antibodies when injected in vivo by itself; (b) specific neutralization of anti-Rh antibodies in vitro; (c) specific neutralization of anti-Rh antibodies in vivo, i. e., desensitization; (d) clinical value in preventing development of erythroblastosis in pregnant women, and (e) clinical value in treatment of erythroblastotic children. Any substance with the aforementioned characteristics may be called a hapten in accordance with Landsteiner's definition3 for substances incapable of generating specific antibodies in vivo but capable of neutralizing specific antibodies in vitro. A potent Rh hapten might have value clinically if it could "desensitize" pregnant sensitized women who would otherwise have erythroblastotic babies and thus permit the
WOLF AM, SCHLUTZ C, FREUNDLICH M, LEVINSON SO. CLINICAL STUDY OF PREVENTION OF ERYTHROBLASTOSIS WITH Rh HAPTEN. JAMA. 1950;144(2):88–92. doi:10.1001/jama.1950.02920020008003
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: